The Association Between Monocyte Subsets and Coronary Collateral Development in Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ugur ARSLAN, Samsun Education and Research Hospital
ClinicalTrials.gov Identifier:
NCT01671306
First received: August 18, 2012
Last updated: August 22, 2012
Last verified: August 2012
  Purpose

Monocyte heterogeneity in peripheral blood seems to be important in coronary collateral development in non-diabetic patients with stable coronary artery disease. Our aim in this study is to find out any possible relationship between the levels of circulating monocyte subsets and coronary collateral development in type 2 diabetic patients.


Condition
Coronary Artery Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Association Between Monocyte Subsets and Coronary Collateral Development in Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Samsun Education and Research Hospital:

Enrollment: 83
Study Start Date: January 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Collateral, coronary disease
Patients are grouped into 2: Good and poor collateral development
collateral
Patients are grouped into 2: Good and poor collateral development

Detailed Description:

83 diabetic patients with severe coronary artery disease were enrolled in the study. These patients were investigated according to their collateral development. Monocytes and their subtypes, namely CD14++CD16- and CD14+CD16+ cells were compared in 2 groups

  Eligibility

Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The study population consisted of 83 consecutive type 2 diabetic patients who have undergone coronary angiography because of stable symptoms and signs of coronary artery disease. The main inclusion criterion was the presence of >95% stenosis of at least one major coronary artery in their first coronary angiogram.

Criteria

Inclusion Criteria:

  • presence of > 95% stenosis of at least one major coronary artery in their first coronary angiogram.

Exclusion Criteria:

  • Patients experiencing acute coronary syndrome either with or without ST elevation in the last one month
  • Evidence of ongoing infection and inflammation, known malignancy and chronic kidney disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01671306

Sponsors and Collaborators
Samsun Education and Research Hospital
Investigators
Principal Investigator: Uğur ARSLAN, MD Samsun Education and Research Hospital
  More Information

No publications provided

Responsible Party: Ugur ARSLAN, Specialist of Cardiology, Samsun Education and Research Hospital
ClinicalTrials.gov Identifier: NCT01671306     History of Changes
Other Study ID Numbers: 1037, Samsun EAH
Study First Received: August 18, 2012
Last Updated: August 22, 2012
Health Authority: Turkey: Ministry of Health

Keywords provided by Samsun Education and Research Hospital:
Coronary collaterals
diabetes mellitus
monocyte subsets

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Diabetes Mellitus
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on July 26, 2014